Gilead ‘Moving Very Quickly’ With FDA on Possible Coronavirus Use, CEO Says
05/01/2020
The maker of Remdesivir, an experimental drug for treatment of the coronavirus, is moving very quickly with the FDA for authorization to get the drug to patients, the CEO of the company, Gilead Sciences, said Friday, according to NBC News.
Gilead is also working to expand its capacity for producing remdesivir, CEO Daniel O’Day told the “TODAY” show in an exclusive interview.
The company thinks it could make millions of treatment courses available by the end of the year, O’Day said. Its production capacity has already gone from 5,000 treatment courses to 100,000, he said.